STOCK TITAN
  1. Home
  2. Sec-filings
  3. CURX
  4. [8-K] Curanex Pharmaceuticals Inc Reports Material Event

[8-K] Curanex Pharmaceuticals Inc Reports Material Event

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Curanex Pharmaceuticals Inc. received an extension from Nasdaq to regain compliance with the $1.00 minimum bid price required for its common stock to remain listed on the Nasdaq Capital Market. The company now has until November 2, 2026 to lift its closing bid price to at least $1.00 for 10 consecutive business days. Curanex is monitoring its share price and may implement a reverse stock split to meet this requirement, but there is no assurance it will succeed, and failure to comply could result in delisting, subject to a potential appeal to a Nasdaq Hearings Panel.

Positive

  • None.

Negative

  • None.

Insights

Nasdaq grants Curanex more time, but delisting risk remains if shares stay below $1.00.

Curanex Pharmaceuticals Inc. has not met Nasdaq’s $1.00 minimum bid price requirement but has received a second 180‑day compliance period, extending its deadline to November 2, 2026. This keeps the stock on the Nasdaq Capital Market for now.

The extension reflects that Curanex meets other Nasdaq listing standards, including market value of publicly held shares, apart from the bid price. To cure the deficiency, the company signaled it may use a reverse stock split if needed to lift the share price above the threshold.

If Curanex does not achieve a closing bid of at least $1.00 for 10 consecutive business days by November 2, 2026, Nasdaq may move to delist the stock. The company could appeal to a Nasdaq Hearings Panel, but the outcome would be uncertain and would depend on subsequent developments.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Initial Nasdaq notice date November 5, 2025 Date Nasdaq informed Curanex of sub-$1.00 bid-price deficiency
Minimum bid price threshold $1.00 per share Required closing bid price for continued Nasdaq Capital Market listing
First compliance deadline May 4, 2026 End of initial 180-day period to regain minimum bid compliance
Extended compliance deadline November 2, 2026 End of additional 180-day period granted by Nasdaq
Required compliant trading period 10 business days Length of time bid must be at least $1.00 to regain compliance
Potential corrective action Reverse stock split Option the company is considering to cure bid-price deficiency
Minimum Bid Price financial
"the closing bid price for its common stock was below $1.00 per share, which is the minimum closing bid price (the “Minimum Bid Price”) required"
The minimum bid price is the lowest share price that a market, regulator, or specific offering will accept for a trade, listing, or auction—think of it as a reserve or floor that a stock must meet to qualify for certain actions. It matters to investors because falling below that floor can limit trading options, trigger compliance measures or delisting risks, and affect liquidity and the perceived value of a holding, much like a reserve price in an auction sets the baseline for a sale.
Nasdaq Listing Rule 5550(a)(2) regulatory
"Minimum Bid Price required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2)"
Nasdaq Listing Rule 5810(c)(3)(A) regulatory
"in accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided with a compliance period of 180 calendar days"
reverse stock split financial
"its intention to cure the deficiency during the second compliance period, by implementing a reverse stock split, if necessary"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
Nasdaq Hearings Panel regulatory
"At that time, the Company may appeal Nasdaq’s determination to a Nasdaq Hearings Panel"
A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.

FAQ

What did Curanex Pharmaceuticals (CURX) announce about its Nasdaq listing?
Curanex disclosed that Nasdaq granted it an additional 180 days, until November 2, 2026, to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company has not yet met that requirement.

What is the minimum bid price requirement affecting Curanex Pharmaceuticals (CURX)?
Nasdaq requires Curanex’s common stock to maintain a closing bid price of at least $1.00 per share for continued listing. The company has traded below this level for an extended period, triggering a deficiency notice and the current compliance deadlines.

How long does Curanex (CURX) have to regain Nasdaq bid-price compliance?
Curanex now has until November 2, 2026, to regain compliance. During this additional 180‑day period, its stock must close at or above $1.00 per share for at least 10 consecutive business days for Nasdaq to confirm compliance.

What steps might Curanex Pharmaceuticals (CURX) take to meet Nasdaq’s requirement?
Curanex stated it is monitoring the closing bid price of its common stock and may implement a reverse stock split, if appropriate, during the second compliance period. Such a split could increase the per‑share price to help satisfy the $1.00 minimum bid condition.

What happens if Curanex (CURX) does not regain Nasdaq compliance by November 2, 2026?
If Curanex cannot demonstrate compliance by November 2, 2026, Nasdaq may notify the company that its securities will be delisted from the Nasdaq Capital Market. Curanex would then have the opportunity to appeal that determination to a Nasdaq Hearings Panel.

Why did Nasdaq grant Curanex (CURX) an additional compliance period?
Nasdaq granted the extra 180‑day period because Curanex met all other applicable initial listing requirements for the Nasdaq Capital Market, including those for market value of publicly held shares, aside from the minimum bid price requirement, which remains unresolved.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false 0002025942 0002025942 2026-05-05 2026-05-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 5, 2026

 

Curanex Pharmaceuticals Inc

(Exact name of registrant as specified in its charter)

 

Nevada   001-42815   83-0741390

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

2 Jericho Plaza, Suite 101B

Jericho, NY

  11753
(Address of principal executive offices)   (Zip Code)

 

(718) 673-6078

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common Stock, par value $0.0001 per share   CURX   The Nasdaq Capital Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 8.01 Other Events

 

As previously reported by Curanex Pharmaceuticals Inc (the “Company”), on November 5, 2025, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the closing bid price for its common stock was below $1.00 per share, which is the minimum closing bid price (the “Minimum Bid Price”) required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Notice”). The Notice indicated that in accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided with a compliance period of 180 calendar days from the date of the Notice, or until May 4, 2026, to regain compliance with the Minimum Bid Price requirement.

 

On May 5, 2026, Nasdaq notified the Company that although the Company has not regained compliance with the Minimum Bid Price Requirement, the Company is eligible to receive an additional 180 calendar day period or until November 2, 2026, to regain compliance with the Minimum Bid Price Requirement. Nasdaq’s determination to grant the Company an additional 180 calendar day period was based on the Company’s satisfaction of the continued listing requirements for the market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement. Additionally, the Company has provided Nasdaq with written notice of its intention to cure the deficiency during the second compliance period, by implementing a reverse stock split, if necessary.

 

If, at any time during this additional compliance period, the closing bid price of the Company’s common stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation of compliance, and this matter will be closed. If compliance cannot be demonstrated by November 2, 2026, Nasdaq will provide written notification that the Company’s securities will be delisted. At that time, the Company may appeal Nasdaq’s determination to a Nasdaq Hearings Panel.

 

The Company is currently monitoring the closing bid price of its common stock and will consider available options, including a reverse stock split, if appropriate, to regain compliance with the Minimum Bid Price Requirement by November 2, 2026. There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement, even if it maintains compliance with other listing requirements of the Nasdaq Capital Market.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Curanex Pharmaceuticals Inc
     
Date: May 7, 2026 By: /s/ Jun Liu
  Name: Jun Liu
  Title: Chief Executive Officer

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents